Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Vodafone Group Plc American Depositary Shares (VOD) Price & Performance

Oruka Therapeutics Inc. Common StockTrade
Vodafone Group Plc American Depositary SharesTrade

Price performance (Past 24H)

Key statistics

Oruka Therapeutics Inc. Common Stock vs Vodafone Group Plc American Depositary Shares — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B), while Vodafone Group Plc American Depositary Shares trades at $15.88 (market cap $36.16B). The key difference: Vodafone Group Plc American Depositary Shares is far larger — about 7.1× Oruka Therapeutics Inc. Common Stock's market cap, and Vodafone Group Plc American Depositary Shares pays a 3.46% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Vodafone Group Plc American Depositary Shares for 5 Days on average.

ORKAVOD
Market Cap
$5.08B$36.16B
Volume
685,2766,634,765
Sector
HealthMedia
52-Week High
$113.08$17.68
52-Week Low
$26.19$11.20
Typical Hold Time
0 Days5 Days
Enterprise Value
$4.21B$81.31B
Dividend Yield
—3.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Oruka Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Vodafone Group Plc American Depositary Shares

VOD trades at $15.555, up 1.07% today, amid a bearish technical signal. The company reported a net loss of $4.17B for 2025, though revenue grew to $37.45B. Positive cash flow from operations of $15.37B and a low EV/EBITDA of 4.33 suggest underlying value. Recent news highlights Vodafone's strategic focus on 5G rollout and cost synergies in the UK, targeting £1 billion by 2032.

The outlook is mixed; analyst consensus leans buy (48%) with potential from operational improvements, but risks include persistent net losses, high debt, and competitive pressures. The stock's current valuation metrics (P/S 0.82, P/B 0.64) indicate it may be undervalued if turnaround efforts succeed.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ORKA
100% Buy0% Sell
Avg holding period · 0 Days
VOD

No sentiment data available yet.

About Oruka Therapeutics Inc. Common Stock

Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.

Read more on ORKA →

About Vodafone Group Plc American Depositary Shares

Vodafone provides mobile, fixed-line, broadband, and business communications services. It operates across Europe and Africa.

Read more on VOD →